Tryp Therapeutics

Tryp Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for rare and orphan diseases, as well as other conditions with significant unmet medical needs. The company's primary focus is on neuropsychiatric disorders, utilizing synthetic psilocybin and its active metabolite, psilocin, in conjunction with psychotherapy. Tryp's lead development program, known as PFN, aims to address these disorders through therapeutic dosing of these compounds. Among its notable candidates is TRP-8802, targeting fibromyalgia, a chronic pain condition, and TRP-1001, an oral formulation of razoxane for soft tissue sarcoma. Founded in 2019 and headquartered in Kelowna, Canada, Tryp Therapeutics emphasizes the exploration of novel drug formulations and methodologies to improve patient outcomes in populations lacking effective treatment options.